Amgen Sizes Up Strategy: Small-Scale Acquisitions, Large-Scale R&D
Executive Summary
Amgen's growth strategy calls for heavy investment in research & development and targeted agreements to expand its pipeline, rather than large-scale acquisitions, CEO Kevin Sharer said
You may also be interested in...
Genentech’s Forecast: Biotech Pioneer Looking To Small Molecules
Genentech, one of the pioneers of the biotech industry, will be bringing a growing number of small molecules into the clinic as it seeks to diversify its pipeline, according to VP-Clinical Hematology/Oncology David Schenkein
Genentech’s Forecast: Biotech Pioneer Looking To Small Molecules
Genentech, one of the pioneers of the biotech industry, will be bringing a growing number of small molecules into the clinic as it seeks to diversify its pipeline, according to VP-Clinical Hematology/Oncology David Schenkein
Roche Re-Models Around Disease Areas, Pulls Together R&D And Commercial
Roche is taking a dual approach in reorganizing its global R&D business by centering on key disease areas and consolidating its full operations, from R&D to marketing, along those lines